Home

Pfizer (PFE)

24.36
-0.30 (-1.23%)
NYSE · Last Trade: Nov 4th, 1:33 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close24.66
Open24.39
Bid24.35
Ask24.36
Day's Range24.31 - 25.20
52 Week Range20.92 - 28.14
Volume108,491,968
Market Cap136.56B
PE Ratio (TTM)12.96
EPS (TTM)1.9
Dividend & Yield1.720 (7.06%)
1 Month Average Volume59,978,373

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

These S&P500 stocks have an unusual volume in today's sessionchartmill.com
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.
Via Chartmill · November 4, 2025
Pfizer (PFE) Q3 2025 Earnings Call Transcriptfool.com
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 4, 2025
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billioninvestors.com
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Via Investor's Business Daily · November 4, 2025
Dow Dips Over 400 Points; Pfizer Earnings Top Estimatesbenzinga.com
Via Benzinga · November 4, 2025
Earnings Scheduled For November 4, 2025benzinga.com
Via Benzinga · November 4, 2025
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Risestocktwits.com
Via Stocktwits · November 4, 2025
Check Out What Whales Are Doing With PFEbenzinga.com
Via Benzinga · November 3, 2025
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Mattersstocktwits.com
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.
Via Stocktwits · November 4, 2025
Pfizer’s (NYSE:PFE) Q3 Earnings Results: Revenue In Line With Expectations
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffsbenzinga.com
Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.
Via Benzinga · November 4, 2025
Is Eli Lilly a Millionaire Maker?fool.com
Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.
Via The Motley Fool · November 4, 2025
Zoetis (NYSE:ZTS) Reports Q3 In Line With Expectations But Stock Drops
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer Raises Profit Outlook Even As Third-Quarter Sales Declineinvestors.com
Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view.
Via Investor's Business Daily · November 4, 2025
Pfizer Inc (NYSE:PFE) Reports Q3 2025 Earnings Beat and Raises Full-Year Profit Guidancechartmill.com
Pfizer Q3 2025 earnings beat estimates and the company raised its full-year profit guidance, highlighting strong cost management and non-COVID portfolio growth.
Via Chartmill · November 4, 2025
Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimatesstocktwits.com
The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.
Via Stocktwits · November 4, 2025
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
By Pfizer Inc. · Via Business Wire · November 4, 2025
Pfizer Tops EPS Expectations In Q3 2025 Despite Revenue Declinetalkmarkets.com
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
Via Talk Markets · November 4, 2025
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?fool.com
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.
Via The Motley Fool · November 4, 2025
Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analystsbenzinga.com
Via Benzinga · November 4, 2025
Uber, AMD And 3 Stocks To Watch Heading Into Tuesdaybenzinga.com
Stock futures trading lower, watch Uber, Upwork, AMD, Starbucks, Pfizer earnings. Starbucks forms China JV. Cramer advises against AT&T.
Via Benzinga · November 4, 2025
Michael Burry Is Super-Bearish On Palantir — With 5 Million Putsbenzinga.com
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.
Via Benzinga · November 3, 2025
Tech Titans Unite and Consumer Giants Merge: Amazon-OpenAI Partnership and Kenvue Buyout Ignite S&P 500 and Nasdaq Gains
November 3, 2025 – The U.S. stock markets are experiencing a significant surge today, with both the S&P 500 and Nasdaq Composite pushing towards new highs. This bullish sentiment is largely fueled by two monumental corporate announcements: a strategic $38 billion partnership between Amazon Web Services (AWS) and OpenAI,
Via MarketMinute · November 3, 2025
Did Novo Nordisk Just Say "Checkmate" to Pfizer?fool.com
These two leading drugmakers are fighting over a promising GLP-1 candidate.
Via The Motley Fool · November 3, 2025
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session.chartmill.com
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · November 3, 2025
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvoinvestors.com
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Via Investor's Business Daily · November 3, 2025